Skip to main content
OpenTrials
Completed

NCT Number: NCT03797781

Protein Ingestion and Skeletal Muscle Atrophy

The effect of different protein intakes on skeletal muscle atrophy during short term unilateral leg immobilisation.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–35 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

Sport and Health Science

Exeter, Devon, EX1 2LU, United Kingdom

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • BMI >18 and <28 no prescription medications or current illness.

Exclusion criteria

  • BMI <18 and >28 current prescription medication no history of leg injury.
  • Smoker
  • Medical conditions including (cardiovascular disease ((e.g. hypertension)), metabolic disease ((e.g. type 2 diabetes)), any personal or family history of deep vein thrombosis.

Treatment and study plan

Lower limb immobilisation (leg brace) with varying levels of protein intake

Other

Single leg immobilisation via leg brace and crutches, the groups have different amounts of protein intake

Primary outcomes

  1. Muscle size

    Time frame: 3 days

Secondary outcomes

  1. Muscle strength

    Time frame: 3 days

Sponsors and collaborators

Lead sponsor

University of Exeter

Other

Registry information

Official study title

Understanding the Role of Protein Ingestion on Skeletal Muscle Atrophy During an Acute Period of Disuse

Important dates

Study start
2017
Primary completion
2019
Study completion
2019
First posted
Jan 9, 2019
Registry last updated
Sep 28, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.